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Abstract ACE 2, a novel homologue of angiotensin converting
enzyme, has recently been identi¢ed. This study used QRT-PCR
to quantitatively map the transcriptional expression pro¢le of
ACE 2 (and the two isoforms of ACE) in 72 human tissues.
While con¢rming that ACE 2 expression is high in renal and
cardiovascular tissues, the novel observation has been made that
ACE 2 shows comparably high levels of expression in the gas-
trointestinal system, in particular in ileum, duodenum, jejunum,
caecum and colon. Therefore, in probing the functional signi¢-
cance of this novel peptidase, some consideration should be giv-
en to a role in gastrointestinal physiology and pathophysiology.
* 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Angiotensin converting enzyme (ACE) catalyses the forma-
tion of angiotensin II from angiotensin I, thereby playing a
key role in the control of cardio-renal function and blood
pressure control [1]. Speci¢c inhibitors of this enzyme are
one of the most widely prescribed classes of drugs in cardiol-
ogy and are used in the treatment of hypertension and heart
failure. At a molecular level, human endothelial ACE was ¢rst
cloned in 1988 by Soubrier and colleagues [2] and character-
ised as a 170-kDa glycoprotein containing two homologous
active sites. Subsequently, it was revealed that a shorter testis
speci¢c isoform occurs which results from alternative splicing
of the same gene [3,4]. In addition, evidence also exists [5] for
a further product of alternative splicing of the ACE gene
resulting in excision of the exons encoding the transmembrane
domain and thereby encoding a soluble form of the enzyme.
More recently, parallel independent publications from two
groups [6,7] revealed a novel gene which encodes a previously
unidenti¢ed homologue of ACE which has been termed ACE
2 [6] or ACEH [7]. In its catalytic domain, this novel enzyme
has approximately 42% identical residues with endothelial
ACE. Both the groups reporting the discovery of this novel
metalloproteinase also made signi¢cant strides in the initial
characterisation of its activity. Importantly, ACE 2 is insensi-
tive to classical small molecule inhibitors of human endothe-
lial ACE such as captopril, lisinopril and enalaprilat [7]. Thus,
if ACE 2 is shown to be of pathophysiological importance, it
represents a novel target for medicinal chemistry driven drug
discovery. In terms of enzymatic activity, ACE 2 also di¡ers
signi¢cantly from endothelial ACE in that it does not catalyse
the formation of angiotensin II. Indeed, ACE 2 cleaves the C-
terminal amino acid of angiotensin II to form angiotensin 1^7
[7,8] suggesting that ACE 2 may act to provide negative feed-
back regulation on the activity of the renin^angiotensin sys-
tem. However, it has been shown that ACE 2 can also e⁄-
ciently cleave the C-terminal residue from several peptides
(apelin-13, dynorphin A 1^13) unrelated to the renin^angio-
tensin system [8]. Both of the groups which independently
identi¢ed ACE 2 [6,7] used multi-tissue Northern blotting to
gain an initial impression of tissue distribution and found that
ACE 2 is expressed in human heart, kidney and testis, con-
sistent with a possible role in cardio-renal function. However,
further clari¢cation and quanti¢cation of the tissue distribu-
tion of ACE 2 is important to help highlight the tissues to
study to help elucidate the physiological role(s) of this novel
enzyme and possible therapeutic target. In the present study,
the quantitative and highly sensitive technique of quantitative
reverse transcriptase polymerase chain reaction (QRT-PCR)
has been applied to study the transcriptional expression pro-
¢le of ACE-2 (relative to the other known isoforms of ACE)
throughout the human body.
2. Materials and methods
Total RNA was extracted from 72 human tissues (three donors/
tissue). Tissues were obtained with approval from the appropriate
ethics committees and through partnership with medical intermedia-
ries, hospitals and tissue banks and in all cases with the full informed
consent of the donor or their next of kin. Prior to RNA extraction,
tissues were assessed histologically by a quali¢ed pathologist and only
used if characterised as non-diseased. Tissues were chosen to represent
major organ systems of the human body. RNA was extracted using
TriZol (Invitrogen Life Technologies), a commercially available mix-
ture of organic solvents. The extractions were carried out as detailed
in the manufacturer’s protocols. Determining the optical density at
260 and 280 nm assessed the concentration and purity of the RNA.
RNA was only used in these studies if the ratio between the 260 nm
and 280 nm readings was greater than 1.7. All RNA solutions were
diluted to 1 Wg/Wl in nuclease free water containing RNase inhibitor
(N808-0119, Applied Biosystems). The quality of the isolated total
RNA was assessed by two methods. Firstly the RNA samples were
run down denaturing agarose gels, only samples that had intact 18S
and 28S ribosomal bands were used for the study. Secondly, it was
determined whether the samples were of high enough quality to be
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used in QRT-PCR, this was done by determining whether the samples
were able to produce robust ampli¢cation of actin and transferrin
receptor mRNA transcripts.
Detection of speci¢c mRNAs was carried out by QRT-PCR using
the ABI Prism 7700 Sequence Detection System (Applied Biosystems)
using previously described methodology [9].
Forward and reverse primers and the £uorogenic probes were de-
signed to the targets of interest using Primer Express software (Ap-
plied Biosystems). The sequences of the primer probe sets used are as
follows:
ACE 2, accession number AF291820.
This primer probe ampli¢es a 107 bp region of the mRNA and was
designed in the same region as the probe that was used in the North-
ern blot experiments previously described [6].
ACE, accession number M26657. This set is a generic set which
picks up both the testicular and somatic form.
This primer probe set ampli¢es a 68 bp region of the mRNA.
ACE-testicular, accession number X16295. This set is speci¢c for
the testicular form.
This primer probe set will pick up a 80 bp sequence of the mRNA.
In addition, the following set was used to amplify a 71 bp portion
of the human glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
transcript that spans an exon/exon boundary. This transcript is ubiq-
uitously expressed and was used as an internal positive control within
the assay.
All the probes were quenched with carboxytetramethyl rhodamine
and all the target probes, with the exception of GAPDH, were la-
belled with the £uor 6-carboxy£uorescein, GAPDH used the £uor
VIC.
The primer/probe sets were homology searched to ensure that they
were speci¢c using an NCBI BLAST search.
3. Results
The quantitative expression map for ACE, ACE testicular
and ACE 2 across 72 human tissues is shown in Fig. 1. As
anticipated, the testicular form of ACE is expressed almost
exclusively in the testis (54 000 copies) with trace expression
(6 10 copies) in jejunum, pancreas and spleen. The expression
map for ACE demonstrates a widespread and ubiquitous dis-
tribution. Expression is particularly high in ileum, jejunum,
duodenum, testis, lung, pulmonary blood vessels and prostate.
ACE 2 is also expressed in many tissues but shows a less
ubiquitous pro¢le than ACE. ACE 2 is highly expressed in
testis, renal and cardiovascular tissues and notably also in
tissues from the gastrointestinal system including ileum, duo-
denum, jejunum, caecum and colon. Expression of ACE 2 was
highest in ileum (copy number = 282 000) of all the 72 tissues
evaluated. Expression of ACE 2 was limited in central nervous
system and lymphoid tissues.
While previous observations [6,7] suggested that ACE 2
should be highly expressed in cardio-renal tissues, the high
expression of ACE 2 in gastrointestinal tissues was unantici-
pated. Since the initial body-wide expression pro¢ling was
restricted to three donors/tissue, experiments were completed
in key tissues (ileum, duodenum, caecum, colon, kidney, (cor-
tex, pelvis, medulla) and heart left ventricle) from a further
three donors to con¢rm the initial observations. The results
(Fig. 2) con¢rm that ACE 2 is expressed at high levels in
gastrointestinal and cardio-renal tissues. Statistical analysis
indicates that while there was no signi¢cant di¡erence in ex-
pression between ileum and duodenum, ACE 2 expression in
ileum and duodenum was signi¢cantly higher than in the car-
dio-renal tissues.
All samples had high GAPDH mRNA expression (s 10 000
copies) indicating that they were of high quality.
4. Discussion
The discovery in 2000 of ACE 2, a novel homologue of
ACE, has raised signi¢cant interest and many laboratories
are now working to elucidate the full physiological and patho-
physiological signi¢cance of this novel enzyme. To that end,
in this study we have used the highly sensitive technique of
QRT-PCR to determine the level of expression of ACE, ACE
testicular and ACE 2 in a wide range of human tissues.
Using QRT-PCR, the human tissue expression pro¢le ob-
tained for somatic and testicular forms of ACE is consistent
generally with published data on the expression and physio-
logical signi¢cance of these enzymes. Thus, as previously re-
ported [4], the testicular form of ACE is expressed almost
exclusively in the testis with trace expression in jejunum, pan-
creas and spleen. The trace expression that is seen in jejunum,
pancreas and spleen is a real signal and cannot be from any
contaminating DNA as the primer probe set spans an exon/
exon boundary and as such will not work on genomic DNA.
This demonstrates the exquisite sensitivity of the technique
and is the ¢rst observation to our knowledge of the testicular
ACE isoform outside of the testis.
For somatic ACE, the primer probe set was a generic set,
which detects both the testicular and somatic forms of the
enzyme. The expression map for ACE demonstrates a wide-
spread distribution with high expression in cardio-renal tis-
sues, consistent with the known physiological importance of
this enzyme. Expression of ACE is also high in ileum, jeju-
num, duodenum, testis, lung, pulmonary blood vessels and
prostate. These results are in concordance with previous stud-
ies, which have assessed the expression and activity of ACE in
human tissue [10,11].
Having used QRT-PCR to demonstrate that the expression
patterns of somatic and testicular ACE are consistent with
previous ¢ndings, we moved on to study the expression pro¢le
of ACE 2 across 72 human tissues. We were particularly in-
terested in looking at ACE 2 as it may be a potential ther-
apeutic target for drug discovery.
QRT-PCR demonstrates that ACE 2 is expressed in many
tissues but shows a less ubiquitous expression pro¢le than
ACE. ACE 2 is highly expressed not only in testis, renal
and cardiovascular tissues, but surprisingly also in tissues
from the gastrointestinal system including ileum, duodenum,
jejunum, caecum and colon. Its expression in central nervous
system and lymphoid tissues was moderate. The present data
are consistent with previous observations [6,7] suggesting that
ACE 2 is highly expressed in cardio-renal tissues, and with
Forward: CATTGGAGCAAGTGTTGGATCTT
Reverse: GAGCTAATGCATGCCATTCTCA
Probe: CTTGCAGCTACACCAGTTCCCAGGCA
Forward: CCGAAATACGTGGAACTCATCAA
Reverse: CACGAGTCCCCTGCATCTACA
Probe: CAGGCTGCCCGGCTCAATGG
Forward: ACGGCCCACCAGACATCA
Reverse: TCATATTCCTCCACAAACTTGCTG
Probe: CAGAGCCCAAACCTGGTGACTGATGA
Forward: GAAGGTGAAGGTCGGAGTCAAC
Reverse: CAGAGTTAAAAGCAGCCCTGGT
Probe: TTTGGTCGTATTGGGCGCCT
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recent data supporting an important role of ACE 2 as a reg-
ulator of cardiac function [12]. However, our data are in con-
trast to those reported in an earlier study in which expression
of ACE 2 in gastrointestinal tissues was reported to be low [6].
We have shown for the ¢rst time signi¢cant expression of
ACE 2 in the small intestine, an observation previously missed
using Northern blotting technique [6,7]. On the basis of these
interesting initial ¢ndings, we decided to expand the observa-
tions to six donors for the key cardiac, renal and gastrointes-
tinal tissues of interest. The data for the six donors con¢rmed
the observation that ACE 2 is highly expressed in gastrointes-
tinal tissue. Statistical analysis of these data showed that the
expression of ACE 2 in ileum and duodenum was signi¢cantly
higher than in any other tissue studied. It is not clear why the
current data di¡er from those of previous workers [6,7] who,
using a Northern blotting approach, had at best detected low
levels of ACE 2 mRNA in gastrointestinal tissues. It seems
unlikely that it re£ects donor variation, in the light of the
consistency of the high levels detected from samples from
six independent donors in the present study. We can therefore
only assume that the failure of the previous studies [6,7] to
identify high levels of ACE 2 gene expression in gastrointes-
tinal tissues re£ects the quality of the RNA used. It is our
experience that for tissues obtained from the gastrointestinal
tract in particular, short postoperative and post mortem delay
times are critical if one is to avoid tissue deterioration and loss
of mRNA integrity (unpublished observations). One limita-
tion of the current study is that we have not demonstrated
cellular localisation of ACE 2 or con¢rmed that there is ACE
2 protein present. It would therefore be bene¢cial to carry out
in situ hybridisation and immunohistochemistry studies in the
gastrointestinal tissues.
In conclusion, this study demonstrates the utility of QRT-
PCR to assess the expression of mRNA transcripts in a wide
range of human tissues. High expression of ACE 2 was seen in
cardio-renal tissues, in agreement with previous results. How-
ever, the identi¢cation of ACE 2 at high levels in gastrointes-
tinal tissues is a novel ¢nding and suggests further experi-
ments are warranted to evaluate the role for ACE 2 in
gastrointestinal physiology and pathophysiology.
Fig. 1. Stellar plot illustrating the mRNA copy number in logarithmic form for ACE (black), ACE 2 (red) and ACE testicular (blue) in 72 hu-
man tissues. Each point represents the geometric mean copy number from determinations in three donors. Gene copy number increases loga-
rithmically moving from the centre to the periphery of the circle. The tissues used are: 1. heart: left atrium; 2. heart: left ventricle; 3. blood
vessel: coronary artery; 4. oesophagus; 5. stomach: fundus; 6. stomach: body; 7. stomach: antrum; 8. stomach: pyloric canal; 9. duodenum;
10. jejunum; 11. ileum; 12. adipose: omental ileum; 13. blood vessel: mesenteric (colon); 14. caecum; 15. colon; 16. rectum; 17. gallbladder;
18. pancreas; 19. liver: parenchyma; 20. brain: cerebellum; 21. brain: hippocampus; 22. brain: locus coeruleus; 23. brain: medulla oblongata;
24. brain: amygdala; 25. brain: caudate; 26. brain: hypothalamus anterior; 27. brain: hypothalamus posterior; 28. brain: cortex: cingulate an-
terior; 29. brain: cortex: cingulate posterior; 30. brain: cortex: frontal-lateral; 31. brain: cortex: frontal-medial; 32. brain: cortex: occipital;
33. brain: cortex: parietal; 34. brain: cortex: temporal; 35. brain: nucleus accumbens; 36. brain: substantia nigra; 37. brain: dorsal raphe nu-
cleus; 38. spinal cord; 39. dorsal root ganglion; 40. pineal gland; 41. pituitary gland; 42. blood vessel: choroid plexus; 43. blood vessel: cere-
bral: middle cerebral artery; 44. trachea; 45. lung: parenchyma; 46. lung: bronchus: primary; 47. lung: bronchus: tertiary; 48. blood vessel:
pulmonary; 49. kidney: cortex; 50. kidney: medulla; 51. kidney: pelvis; 52. blood vessel: renal; 53. ureter; 54. bladder; 55. bladder: trigone;
56. ovary; 57. fallopian tube; 58. uterus: myometrium; 59. uterus: cervix; 60. prostate; 61. vas deferens; 62. testis; 63. spleen: parenchyma;
64. cell : blood mononuclear; 65. lymph gland: tonsil; 66. muscle: skeletal; 67. skin: foreskin; 68. adrenal gland; 69. thyroid gland; 70. umbili-
cal cord; 71. placenta; 72. breast.
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Fig. 2. Quantitative expression pro¢le of ACE 2 in human gastroin-
testinal, renal and cardiovascular tissues. Values are mean copy
numberU 95% (n=6). *P6 0.05, statistically signi¢cant di¡erence
when compared to ileum, þP6 0.05 when compared to duodenum
(one way analysis of variance followed by Newman^Keuls post hoc
test).
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